InSysBio to participate in SITC 2024

events
Conference
October 4, 2024

InSysBio announces its participation in SITC’s 39th Annual Meeting which is to be held from November 6-10, 2024, at George R. Brown Convention Center in Houston, TX, USA. InSysBio team is going to present its Mechanistic modeling services and tools to support development of immunotherapies at Booth #1032 and 3 posters in frames of the Meeting, namely:

Saturday, November 9:

  • 536 "Evaluation of various strategies to unleash DNAM1 signaling and block TIGIT/PVRIG axis" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
  • 1064 "Mechanistic translational modeling to predict first-in-human dose for T-cell engager: HPN536 case study" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
  • 1208 "Comparison of receptor occupancy and optimal doses of PD1xCD40 and PDL1xCD40 bispecific antibodies using physiologically based pharmacokinetic modeling" by Alexandra Diakonova, Dmitry Schelokov, Oleg Demin Jr, Oleg Demin

Check out Booth #1032 and posters at SITC 2024 Annual Meeting!

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

June 2020
MoTuWeThFrSaSu
1
2
1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
3
4
5
1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.
6
7
8
1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
9
10
11
12
1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.
13
14
15
16
17
1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.
18
19
20
21
22
1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website
23
24
25
26
27
28
29
30
1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
     
Upcoming Events
10.11
InSysBio to take part in ACoP 2024
06.11
InSysBio to participate in SITC 2024
Tags
Latest News
10.09
InSysBio team to publish the new article in PSPJournal
04.09
InSysBio to launch Immune Response Template version 3.6.3 for QSP modeling
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator